{
    "clinical_study": {
        "@rank": "133019", 
        "brief_summary": {
            "textblock": "To evaluate the ability of the combination of indinavir, zidovudine, and lamivudine to\n      suppress HIV-1 infection as measured by: (1) the maintenance of HIV-1 serum viral RNA below\n      the limit of detection of the most sensitive validated assay (ultradirect assay) and (2)\n      absence of evidence of infectious virus in lymph node, cerebrospinal fluid (CSF), peripheral\n      mononuclear cells (PBMCs), and semen.\n\n      It is hypothesized that the administration of indinavir, zidovudine, and lamivudine will\n      result in:\n\n        1. No evidence of infectious virus in lymph node tissue, CSF, PBMCs, and semen samples in\n           50% of patients who have undetectable viral RNA by the most sensitive validated assay\n           available (ultradirect assay) for at least 48 weeks.\n\n        2. Sustained suppression of HIV-1 infection as measured by a decrease in serum viral RNA\n           to below the limit of detection of the ultradirect assay for at least 48 weeks in at\n           least 25% of patients.\n\n        3. Suppression of HIV-1 infection as measured by a decrease in serum viral RNA to below\n           the limit of detection of the standard Amplicor assay (i.e., negative) in at least 90%\n           of patients by Week 16.\n\n        4. Suppression of HIV-1 infection, suggesting eradication of the virus as measured by\n           maintenance of serum viral RNA to below the limit of detection of the ultradirect assay\n           for at least 24 weeks after discontinuation of indinavir, zidovudine, and lamivudine in\n           patients who have maintained this level of suppression for at least 120 weeks on\n           therapy."
        }, 
        "brief_title": "The Effectiveness of Indinavir Plus Zidovudine Plus Lamivudine in HIV-Infected Patients With No Symptoms of Infection", 
        "condition": "HIV Infections", 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome"
            ]
        }, 
        "detailed_description": {
            "textblock": "It is hypothesized that the administration of indinavir, zidovudine, and lamivudine will\n      result in:\n\n        1. No evidence of infectious virus in lymph node tissue, CSF, PBMCs, and semen samples in\n           50% of patients who have undetectable viral RNA by the most sensitive validated assay\n           available (ultradirect assay) for at least 48 weeks.\n\n        2. Sustained suppression of HIV-1 infection as measured by a decrease in serum viral RNA\n           to below the limit of detection of the ultradirect assay for at least 48 weeks in at\n           least 25% of patients.\n\n        3. Suppression of HIV-1 infection as measured by a decrease in serum viral RNA to below\n           the limit of detection of the standard Amplicor assay (i.e., negative) in at least 90%\n           of patients by Week 16.\n\n        4. Suppression of HIV-1 infection, suggesting eradication of the virus as measured by\n           maintenance of serum viral RNA to below the limit of detection of the ultradirect assay\n           for at least 24 weeks after discontinuation of indinavir, zidovudine, and lamivudine in\n           patients who have maintained this level of suppression for at least 120 weeks on\n           therapy.\n\n      All patients receive indinavir plus zidovudine plus lamivudine for at least 96 weeks. If\n      there is no evidence of infectious virus, and patients continue to have serum viral RNA\n      levels below the limit of detection of the ultradirect assay for at least 96 weeks, therapy\n      is continued for an additional 24 weeks. However, during this additional 24 weeks of therapy\n      patients may continue to receive this triple combination drug regimen or make changes to\n      this drug regimen treatment by reducing their number of antiretroviral agents. After 120\n      weeks, if patients continue to have serum viral RNA levels below the limit of detection of\n      the ultradirect assay, patients discontinue all antiretroviral therapy. However, if there is\n      any evidence of infectious virus, as outlined above, patients do not discontinue therapy.\n      Patients who develop detectable serum viral RNA following discontinuation of therapy are\n      given the option to reinitiate therapy with the triple combination of indinavir, zidovudine\n      and lamivudine. NOTE: Patients who develop an intolerance to zidovudine may use stavudine at\n      doses per body weight at the direction of the investigator."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        Patients must have:\n\n          -  HIV-1 seropositive status.\n\n          -  CD4 count >= 500 cells/mm3.\n\n          -  Serum viral RNA level > 1000 copies/ml.\n\n        Exclusion Criteria\n\n        Prior Medication:\n\n        Excluded:\n\n        Previous antiretroviral therapy."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": "200", 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00002179", 
            "org_study_id": "246G", 
            "secondary_id": "MK-0639"
        }, 
        "intervention": [
            {
                "intervention_name": "Indinavir sulfate", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "Lamivudine", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "Zidovudine", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Zidovudine", 
                "Lamivudine", 
                "Reverse Transcriptase Inhibitors", 
                "Indinavir", 
                "HIV Protease Inhibitors"
            ]
        }, 
        "keyword": [
            "Semen", 
            "Monocytes", 
            "HIV-1", 
            "Drug Therapy, Combination", 
            "Zidovudine", 
            "Lymph Nodes", 
            "HIV Protease Inhibitors", 
            "Lamivudine", 
            "Indinavir", 
            "RNA, Viral", 
            "Reverse Transcriptase Inhibitors", 
            "Anti-HIV Agents", 
            "Viral Load"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Birmingham", 
                        "country": "United States", 
                        "state": "Alabama", 
                        "zip": "352942050"
                    }, 
                    "name": "Univ of Alabama at Birmingham"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Los Angeles", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90033"
                    }, 
                    "name": "LAC - USC Med Ctr"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Redwood City", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "94063"
                    }, 
                    "name": "AIDS Community Research Consortium"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Francisco", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "94110"
                    }, 
                    "name": "San Francisco Gen Hosp"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New Haven", 
                        "country": "United States", 
                        "state": "Connecticut", 
                        "zip": "06510"
                    }, 
                    "name": "Yale Univ School of Medicine / AIDS Program"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chicago", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "606123832"
                    }, 
                    "name": "Rush Presbyterian - Saint Luke's Med Ctr / Infect Dis"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Baltimore", 
                        "country": "United States", 
                        "state": "Maryland", 
                        "zip": "21287"
                    }, 
                    "name": "Johns Hopkins Hosp"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02114"
                    }, 
                    "name": "Harvard (Massachusetts Gen Hosp)"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02215"
                    }, 
                    "name": "Beth Israel Deaconess Med Ctr - East Campus"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02115"
                    }, 
                    "name": "Brigham and Women's Hosp"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02115"
                    }, 
                    "name": "Fenway Community Health Ctr"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10016"
                    }, 
                    "name": "NYU Med Ctr"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Stony Brook", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "117948153"
                    }, 
                    "name": "Univ Hosp / SUNY at Stony Brook / AIDS TMT Unit"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Pittsburgh", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "15213"
                    }, 
                    "name": "Pitt Treatment Ctr"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Providence", 
                        "country": "United States", 
                        "state": "Rhode Island", 
                        "zip": "02906"
                    }, 
                    "name": "Brown Univ / Miriam Hosp"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Vancouver", 
                        "country": "Canada", 
                        "state": "British Columbia"
                    }, 
                    "name": "Saint Paul's Hosp"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Montreal", 
                        "country": "Canada", 
                        "state": "Quebec"
                    }, 
                    "name": "Montreal Gen Hosp"
                }
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Canada"
            ]
        }, 
        "official_title": "A Multiclinic, Open Study to Evaluate the Ability of the Combination of Indinavir, Zidovudine and Lamivudine to Result in Sustained Suppression of HIV-1 in Asymptomatic HIV-1 Seropositive Patients", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 4", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00002179"
        }, 
        "source": "NIH AIDS Clinical Trials Information Service", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Merck Sharp & Dohme Corp.", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "Endpoint Classification: Efficacy Study, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 1999"
    }, 
    "geocoordinates": {
        "AIDS Community Research Consortium": "37.485 -122.236", 
        "Beth Israel Deaconess Med Ctr - East Campus": "42.358 -71.06", 
        "Brigham and Women's Hosp": "42.358 -71.06", 
        "Brown Univ / Miriam Hosp": "41.824 -71.413", 
        "Fenway Community Health Ctr": "42.358 -71.06", 
        "Harvard (Massachusetts Gen Hosp)": "42.358 -71.06", 
        "Johns Hopkins Hosp": "39.29 -76.612", 
        "LAC - USC Med Ctr": "34.052 -118.244", 
        "Montreal Gen Hosp": "45.509 -73.554", 
        "NYU Med Ctr": "40.714 -74.006", 
        "Pitt Treatment Ctr": "40.441 -79.996", 
        "Rush Presbyterian - Saint Luke's Med Ctr / Infect Dis": "41.878 -87.63", 
        "Saint Paul's Hosp": "49.261 -123.114", 
        "San Francisco Gen Hosp": "37.775 -122.419", 
        "Univ Hosp / SUNY at Stony Brook / AIDS TMT Unit": "40.926 -73.141", 
        "Univ of Alabama at Birmingham": "33.521 -86.802", 
        "Yale Univ School of Medicine / AIDS Program": "41.308 -72.928"
    }
}